• Asian Pacific Journal of Cancer Prevention
• /
• 제13권9호
• /
• pp.4215-4220
• /
• 2012

AML (Acute myeloid leukemia) is a form of blood cancer where growth of myeloid cells occurs in the bone marrow. The prognosis is poor in general for many reasons. One is the presence of leukaemia-specific recognition markers such as FLT3 (fms-like tyrosine kinase 3). Another name of FLT3 is stem cell tyrosine kinase-1 (STK1), which is known to take part in proliferation, differentiation and apoptosis of hematopoietic cells, usually being present on haemopoietic progenitor cells in the bone marrow. FLT3 act as an independent prognostic factor for AML. Although a vast literature is available about the association of FLT3 with AML there still is a need of a brief up to date overview which draw a clear picture about this association and their effect on overall survival.

• 한국한의학연구원논문집
• /
• 제10권1호
• /
• pp.127-135
• /
• 2004

Hematopoietic stem cells in bone marrow form all kinds of blood cells. In traditional medicine, functions of bone marrow cells are very similar to those of Essence(精) which is a fundamental factor of physical development and reproduction. Our experiment examined the effect of deer blood on aplastic anemia induced mouse using cyclophosphamide 150 mg/kg i.p injection before experiment and then another cyclophosphamide 120 mg/kg i.p injection on day 10. Then we administrated dried deer blood in distilled water for 5 days, 9 days and 10 days. We examined blood and marrow samples. In results, deer blood showed a trend of effectiveness on recovery of red blood cells and erythropoietin although they were not statistical significant. And deer blood did not show changes in CD34.

• 대한임상검사과학회지
• /
• 제38권1호
• /
• pp.9-15
• /
• 2006

Peripheral bood stem cell collection (PBSCC), including peripheral blood stem cell transplantation (PBSCT), has been utilized worldwide as a very beneficial treatment method instead of allogenic Bone Marrow Transplantation (BMT) because it has many advantages such as rapid bone marrow engraftment and hematopoietic recovery, easy and safe accessibility and lower risk of rejection compared with allogenic BMT. In order to identify most the observable parameter in PBSCC, we analyzed various hematological parameters before and after PBSCC, and evaluated the correlation between the time of bone marrow engraftment and the number of CD34+ cells. Thirteen patients, who underwent 54 PBSCCs from January, 2003 to August, 2004 at Chungnam National University Hospital due to various systemic neoplasms, were analyzed in aspects of various hematological parameters including CD34+ cells using by Flow Cytometry (FCM). PBSCC harvests are described below: Mononuclear cells (MNC) $2.3{\pm}1.4{\times}10^8/kg$ and CD34+ cells $0.63{\pm}0.35{\times}10^6/kg$ on average, respectively. There was a statistical significance in Hb and Hct before and after PBSCC, but not in WBC and platelet counts. The period to reach the hematological bone marrow engraftment was 13.4(10~21) days and 19.5(11~38) days according to the criteria of absolute neutrophile counts (ANC) ${\geq}500/uL$ and platelet counts ${\geq}50,000/{\mu}L$ in peripheral blood, respectively. There was a significant correlation between the numbers of CD34+ cell and ANC (p<0.05), and a borderline significance between MNC and ANC (p=0.051). We found that a group of patients, who were infused with CD34+ cells more than $3.5{\times}10^6/kg$, reached more rapidly the period of bone marrow engraftment in platelet counts (p=0.040). This present study suggested that Hb and Hct were the most useful parameters and should be closely monitored before and after PBSCC, that a PBSCT with the dosage of more than $3.5{\times}10^6/kg$ of CD34+ cells was needed to perform successful bone marrow engraftment, and additionally that platelet counts could be more useful in indicating bone marrow engraftment than ANC.

• 한국임상수의학회지
• /
• 제7권2호
• /
• pp.451-469
• /
• 1990

The present study was carried out to investigate whether the aloe had a radioprotective effect in mice exposed to cobalt-60 gamma radiation or not. The survival ratio of mice for 30 days, hematopoiesis of blood-forming stem cells by spleen colony assay, chromosomal aberration frequency of bone marrow cells and histopathological findings of bone marrow were investigated. The survival ratios of aloe administered groups with concentration of 250, 500, 1,000 and 1,500mg for 3 days before irradiation and control group in cobalt-60 gamma irradiated mice(700rads whole body irradiation, dose rate of 50rads/min.) were 77.4, 79.3, 80.6, 90.0 and 53.1％, respectively. The survival ratios of pre-irradiation aloe administered groups were superior to those of post-irradiation aloe groups and control group. In spleen colony assay, Aloe vera administration before irradiation enhanced the recoveries of numbers of blood-forming stem cells of bone marrow of irradiated mice. There were decreased chromosomal aberrations of bone marrow cells at the first day after irradiation in aloe administered groups compared to that of control group. Histopathological findings in the bone marrow of irradiated mice were hypocellularity due to the depletion of myelocytes, abundant of fat vacuoles and these changes were weakened in aloe administered groups compared to that of control group.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권17호
• /
• pp.7415-7423
• /
• 2015

Chronic myeloid leukemia (CML) is a stem cell disorder characterized by unrestricted proliferation of the myeloid series that occurs due to the BCR-ABL fusion oncogene as a result of reciprocal translocation t(9;22) (q34;q11). This discovery has made this particular domain a target for future efforts to cure CML. Imatinib revolutionized the treatment options for CML and gave encouraging results both in case of safety as well as tolerability profile as compared to agents such as hydroxyurea or busulfan given before Imatinib. However, about 2-4% of patients show resistance and mutations have been found to be one of the reasons for its development. European Leukemianet gives recommendations for BCR-ABL mutational analysis along with other tyrosine kinase inhibitors (TKIs) that should be administered according to the mutations harbored in a patient. The following overview gives recommendations for monitoring patients on the basis of their mutational status.

• Asian Pacific Journal of Cancer Prevention
• /
• 제17권3호
• /
• pp.923-926
• /
• 2016

The classic BCR-ABL1-negative myeloproliferative neoplasm is an operational sub-category of MPNs that includes polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The JAK2V617F mutation is found in ~ 95% of PV and 50-60% of ET or PMF. In most of the remaining JAK2V617F-negative PV cases, JAK2 exon 12 mutations are present. Amongst the JAK2V617F-negative ET or PMF 5-10% of patients carry mutations in the MPL gene. Prior to 2013, there was no specific molecular marker described in the remaining 30-40% ET and PMF. In December 2013, two research groups independently reported mutations in the gene CALR found specifically in ET (67-71%) and PMF (56-88%) but not in PV. Initially CALR mutations were reported mutually exclusive with JAK2 or MPL. However, co-occurrence of CALR mutations with JAK2V617F has been reported recently in a few MPN cases. Many studies have reported important diagnostic and prognostic significance of CALR mutations in ET and PMF patients and CALR mutation screening has been proposed to be incorporated into WHO diagnostic criteria for MPN. It is suggestive in diagnostic workup of MPN that CALR mutations should not be studied in MPN patients who carry JAK2 or MPL mutations. However JAK2V617F and CALR positive patients might have a different phenotype and clinical course, distinct from the JAK2-positive or CALR-positive subgroups and identification of the true frequency of these patients may be an important factor for defining the prognosis, risk factors and outcomes for MPN patients.

• 환경생물
• /
• 제31권3호
• /
• pp.189-191
• /
• 2013

Mycotoxins such as aflatoxin B1 (AFB1), ochratoxin A (OTA) and zearalenone (ZEA) are widespread contaminants of food and feedstuffs. It is very likely, that humans and animals are always exposed to mixtures of mycotoxins rather than to individual compounds. Therefore, risk assessments should consider mixture toxicity data. In the present study the combination of AFB1, OTA and ZEA was tested for genotoxicity in rat bone marrow and blood leukocytes after 15, 30 and 60 days treatment. The level of DNA damage was determined by the comet assay. The tail intensity and Olive tail moment in leukocytes and bone marrow cells were significantly higher than in controls. At the same time, the level of DNA damage in bone marrow cells was higher than in leukocytes. The data suggests that prolonged exposure to mycotoxins combination through food consumption can induce DNA damage contributing to the harmful effects in vivo.

• Asian-Australasian Journal of Animal Sciences
• /
• 제15권4호
• /
• pp.509-515
• /
• 2002

Copper deficiency was induced in eight male buffalo calves by adding molybdenum (30 ppm wet basis) to their diet. Copper status was monitored from the liver copper concentration and a level below 30 ppm (DM basis) was considered as deficient. Haemoglobin, haematocrit, total and differential leucocyte numbers were determined. The functions of peripheral neutrophils were assessed by in vitro phagocytosis and killing of Staphylococcus aureus. The effect of molybdenum induced copper deficiency on bone marrow was monitored. The mean total leucocyte count was unaffected whereas a significant fall in neutrophil count coincided with the fall in hepatic copper level to $23.9{\pm}2.69$ ppm. Reduced blood neutrophil numbers was not accompanied by any change in the proportion of different neutrophil precursor cells in bone marrow. It was hypothesised that buffalo calves were more tolerant to dietary molybdenum excess than cattle. It was concluded that neutropenia in molybdenum induced copper deficiency occurred without any effect on their synthesis and maturation process. Bone marrow studies in healthy calves revealed higher percentage of neutrophilic myelocytes and metamyelocytes as compared to cattle.

• Tuberculosis and Respiratory Diseases
• /
• 제42권5호
• /
• pp.654-659
• /
• 1995

연구배경: 결핵에서의 혈액학적인 변화는 그 양상이 다양하며, 이러한 변화는 단순폐결핵과 속립성결핵에서 차이가 있다고 알려져 있다. 지금까지 국내에서 단순폐결핵에 대한 말초 혈액의 혈액학적 변화에 대한 연구는 있었으나, 속립성결핵에서의 혈액학적 변화에 대한 보고는 거의 없는 실정이다. 이에 속립성결핵에서 말초혈액 및 골수에서의 혈액학적 변화를 알아보고자 본 연구를 시행하였다. 방법 1993년 8월부터 1994년 7월까지 전북대학교 병원에 입원한 환자들 중 단순흉부방사선사진 및 고해상도 전산화 단층사진상 속립성 결핵 소견을 보이며 객담도말과 배양검사, PCR검사에서 결핵균이 증명되었거나 골수검사에서 결핵성육아종을 보인 10예를 대상으로 하였다. 혈액학적 소견의 평가는 Dacie 등에 의해 기술되어진 정의에 따랐으며 혈액체취는 내원당시에 시행하였고 골수검채는 입원후 7일이내에 시행하였다. 결과: 말초혈액소견상 범혈구감소증 1예, 빈혈은 전예에서 있었으며 백혈구증가증은 10%, 백혈구감소증은 20%, 혈소판감소증은 30%, 임파구감소증은 90%, 단구증가증은 40%, 중성구증가증은 20% 그리고 중성구감소증은 환자의 10%에서 나타났다. 골수검사에서 임파구감소증은 30%, 임파구증가증은 20%, 형질세포감소증은 40%, 단구증가증은 전예(100%)에서 나타났으며, 저세포충실도는 30%, 적혈구조혈감소는 30% 그리고 과립구조혈증가와 감소가 각각 환자의 20%에서 나타났다. 골수육아종소견은 환자의 25%에서 나타났다. 결론: 속립성결핵의 혈액학적 변화는 혈구감소증의 경향을 보였으나 단구는 말초 및 골수 모두에서 증가하는 소견을 보였다. 이러한 소견은 속립성결핵의 감별진단에 있어서 도움을 줄 수 있올 것으로 기대된다.

• BLOOD RESEARCH
• /
• 제53권4호
• /
• pp.281-287
• /
• 2018

Background Bone marrow involvement (BMI) affects the lymphoma stage, survival, and treatment. Bone marrow biopsy (BMB) and fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET/CT) are useful techniques to detect BMI. Both have advantages and disadvantages. We aimed to identify factors that could be used to predict BMI with positive and negative results on PET/CT compare them with BMB in newly diagnosed patients with lymphoma. Methods We included 22 non-Hodgkin and 16 Hodgkin lymphoma patients in this single center study. All patients had PET/CT examination and BMB before treatment. BMI in BMB was reported as negative or positive. Bone marrow was classified into 3 types by FDG uptake on PT/CT; diffuse involvement, focal involvement, and normal bone marrow. Results PET/CT and BMB results were concordant (7 positive, 15 negative) in 22 patients (57%). We evaluated concordant and discordant patient characteristics and risk-stratified patients for BMI. Our findings suggest that patients with diffuse FDG uptake on PET/CT, especially patients with advanced age and low platelet and white blood cell counts, are likely to have BMI and could potentially forego BMB. Patients with negative PET/CT findings and no significant laboratory abnormalities are very unlikely to have BMI. Conclusion Our results suggest that BMI should not be decided solely based PET/CT or BMB findings. It is reasonable to use both diagnostic assays along with clinical and laboratory findings. PET/CT result, clinical and laboratory findings could be useful for predicting BMI in patient for whom BMB is contraindicated.